Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.

Abstract: A device for monitoring adherence of a patient to a prescribed regimen is provided. The device has a pulmonary delivery device fluid, an adapter in communication with the delivery device and a dispenser in fluid communication with the adapter. A pressurized drug, contained in the pulmonary delivery device, can be delivered from the pulmonary delivery device to the patient through the adapter and the dispenser. A sensor is mounted to the adapter or the dispenser for detecting a temperature or pressure change caused by the movement of the drug from the pulmonary delivery device to the patient and generating a feedback signal based on the change. The feedback signal is further processed for generating a signal indicating a successful deliver of the drug to the patient.

Abstract: A device is disclosed for detecting time-resolved optical data, the device comprising a sensor comprising a number of detection elements configured to detect a light signal in a single photon regime, a timing circuit connected to said number of detection elements though a common line, and a control module connected to the sensor, the control module being configured to selectively enable the detection elements of the sensor according to a set of enabling patterns. The timing circuit is configured to measure a time of arrival of an output signal from the detection elements on the common line, the output signal being indicative of the detection of a photon of the light signal by any of the enabled detection elements.

Abstract: A delayed release drug formulation includes a core and a coating. The coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release drug formulation is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A delayed release coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release coating is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A delayed release drug formulation includes a core and a coating. The coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release drug formulation is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A delayed release coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release coating is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: According to an embodiment, a hearing aid system is disclosed. The system includes a speech processor communicatively coupled to a microphone. The speech processor is configured to process a microphone signal received at the speech processor for producing an electrical stimulation signal and an acoustic stimulation signal. The speech processor is also configured to generate a modified acoustic stimulation signal by modifying the acoustic stimulation signal at least for a part of a residual frequency range of a patient in dependence on effect of an implantable electrode array on mechanical properties of cochlea of the patient. The system also includes a first unit and a second unit.

Abstract: A process for depositing an inorganic material on a substrate, the process comprising, providing a substrate having a surface, providing a precursor mixture comprising a metal sulfonate, and delivering the precursor mixture to the surface of the substrate, wherein the surface of the substrate is at a substrate temperature of above 450° C. and is sufficient to effect decomposition of the metal sulfonate. The inorganic material may include a metal or a metal oxide. The preferred metal sulfonate is metal triflate.

Abstract: A method of acquiring magnetic resonance imaging (MRI) data from an MRI scan of an object includes generating a number of excitation sequences by, in order: generating an excitation pulse, generating an imaging magnetic field gradient, and generating a spoiler magnetic field gradient. MRI data is acquired during the generation of the spoiler magnetic field gradients. The spoiler magnetic field gradients are selected such that, during each excitation sequence, substantially the same k-space trajectory is traversed during the generation of the spoiler magnetic field gradient.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A method of acquiring magnetic resonance imaging (MRI) data from an MRI scan of an object includes generating a number of excitation sequences by, in order: generating an excitation pulse, generating an imaging magnetic field gradient, and generating a spoiler magnetic field gradient. MRI data is acquired during the generation of the spoiler magnetic field gradients. The spoiler magnetic field gradients are selected such that, during each excitation sequence, substantially the same k-space trajectory is traversed during the generation of the spoiler magnetic field gradient.

Abstract: The present invention provides a measuring apparatus (200) for measuring properties of a surface (101, 103), the apparatus (200) comprising a mounting structure (210) comprising a plurality of segments (211-216) moveably mounted (217) with respect to each other, an actuation mechanism to move the segments of the mounting structure with respect to each other, and a plurality of sensors (220), each sensor being mounted to a segment of the mounting structure (210). The invention also provides a method of measuring properties of a surface (101, 103). The surface (102, 103) to be measured may be an aerodynamic surface of an aircraft.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.